Open session of the standing technical committee of the EUFMD- 2004

Page 168

Appendix 23 Characterisation of a new type O lineage of FMDV from Uganda with atypical clinical manifestations in domestic cattle Laurids Siig Christensen1*, Rose Okurut2, Kirsten Tjørnehøj1, Preben Normann1, Karl Johan Soerensen1 and Martin Esau2 1 Danish Institute for Food and Veterinary Research, Lindholm, Dk-4771 Kalvehave, Denmark 2 Ministry of Agriculture, Animal Industry and Fisheries, Airport Road, P.O.Box 24, Entebbe, Uganda Abstract During 2000-2003 a disease appeared in domesticated cloven-hoofed animals in Uganda characterised by photophobia, lethargia, abnormal growth of hair, and reduced or arrested lactation. The syndrome became known among farmers and veterinarians as “Otolimo” for “seeking the shade” and it was concluded to be a chronic sequelae of FMDV infection. Isolates from 2002 outbreaks of FMD in Uganda were characterised by full-length sequencing, discriminating antigen ELISA and cross neutralisation tests, which revealed that the isolates were type O. The branch lengths of dendrograms between the Uganda strains and other type O strains were of the same order of magnitude as the ones between the other type O lineages. The appearance of a new type O lineage in domestic cattle in Uganda raises the question if type O was always present on the African continent or if this lineage was reintroduced – and if reintroduced – from where. The continuous identification of new lineages of FMDV also addresses the question if our knowledge of the global diversity of FMDV is still so limited – or if new lineages emerge by distinct jumps from pre-existing ones. Introduction From 2000 to 2003 Uganda has reported between 28 and 38 annual outbreaks of Foot and mouth disease, which is an increase from the 1-15 annual outbreaks reported during 1996-1999. The 20002002 outbreaks included 1200-3100 annual cases, while 27000 cases were reported in 2003 and about 18000 in the first half of 2004. The outbreaks have been caused by strains of serotypes A, O, SAT1, SAT2 and SAT3. In collaboration with the Ministry of Agriculture, Animal Industry and Fisheries in Uganda and FAO, we have had the opportunity to study a number of bovine probang samples collected in 2002 in Kumi district in Uganda. In this paper we present the preliminary results of the characterisation of a new type O lineage. Materials and Methods Clinical signs The clinical description is a summary of local records. Samples Twelve probang samples (EL1 through EL12) were collected from bovines during an outbreak in Kumi district, Uganda, in 2002. Virus was isolated on primary porcine kidney monolayer cell culture (PK cells), and six isolates were subjected to discriminating antigen ELISA according to Have, Lei and Scherning-Thiesen (1984). Production of guinea pig sera Guinea pigs were injected two times intradermally in the footpad of one hind limb with one of two Ugandan isolates (EL7 and EL11). The injections were separated by nine weeks. The inocula consisted of a 1:5 dilution of second passages of the isolates in PK cells, which contained 104.9 TCID50/ml (EL7) and 104.7 TCID50/ml (EL11). Serum samples were obtained after 4 weeks, and tested for antibodies towards FMDV strains O-Manissa, A-Iraque and themselves. Furthermore, the EL7/O-Manissa titre ratio was determined for five guinea pig anti-EL7 or anti-EL11 sera, a pool of these and a guinea pig anti-O-Manissa serum in three separate tests. Cross-neutralisation test A cross-neutralisation study including all seven FMDV serotypes and the Ugandan isolates was performed. Virus included O-Manissa, A-Iraque, C-Noville, Asia1/Shamir, SAT1/Bot1/68, SAT2/Zim5/81, SAT3/Zim4/81 and EL7. The sera included were guinea pig sera raised towards the viruses and a pool of five positive guinea pig anti-EL7 or anti-EL11 sera. Quadruplicates of sera were two-fold serial diluted seven times starting from 1:4 or 1:10 in 96-well culture plates (Nunc). Each 159


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 82

17min
pages 492-500

Appendix 77

22min
pages 468-476

Appendix 78

25min
pages 477-484

Appendix 79

14min
pages 485-489

Appendix 81

1min
page 491

Appendix 80

1min
page 490

Appendix 76

12min
pages 464-467

Appendix 75

1min
page 463

Appendix 64

10min
pages 412-414

Appendix 72

13min
pages 455-460

Appendix 73

1min
page 461

Appendix 65

1min
page 415

Appendix 67

1min
page 424

Appendix 63

34min
pages 401-411

Appendix 62

2min
page 400

Appendix 54

8min
pages 361-363

Appendix 61

15min
pages 394-399

Appendix 55

11min
pages 364-366

Appendix 59

1min
page 385

Appendix 60

20min
pages 386-393

Appendix 56

1min
page 367

Appendix 42

21min
pages 270-276

Appendix 52

10min
pages 350-352

Appendix 50

21min
pages 330-339

Appendix 46

2min
page 307

Appendix 37

7min
pages 241-243

Appendix 38

7min
pages 244-246

Appendix 41

2min
page 269

Appendix 40

15min
pages 255-268

Appendix 36

16min
pages 236-240

Appendix 35

15min
pages 231-235

Appendix 34

25min
pages 224-230

Appendix 28

2min
page 198

Appendix 31

10min
pages 212-215

Appendix 29

16min
pages 199-203

Appendix 33

3min
pages 221-223

Appendix 27

1min
page 197

Appendix 26

27min
pages 188-196

Appendix 25

12min
pages 182-187

Appendix 23

8min
pages 168-171

Appendix 22

28min
pages 158-167

Appendix 15

2min
page 113

Appendix 16

7min
pages 114-116

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min
pages 144-145

Appendix 19

18min
pages 136-143

Appendix 14

4min
page 112

Appendix 13

10min
pages 107-111

Appendix 5

2min
page 64

Appendix 12

9min
pages 104-106

Appendix 3

9min
pages 47-49

Appendix 4

26min
pages 50-63

Appendix 8

12min
pages 77-80

Appendix 2

8min
pages 43-46

Open Session

6min
pages 39-42

Closed Session

2min
pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min
page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min
page 36

Item 14 – Regulatory compliance

2min
page 35

Item 10 – International issues

3min
page 32

Item 9 – Novel vaccines

3min
page 31

Item 7 – Optimisation of conventional vaccines

3min
page 29

Item 4 – Managing diagnostic demands

3min
page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min
page 30

Item 3 – Transmission and its control

3min
page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min
page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min
page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min
page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min
page 20
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.